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62. Abstract 
2.1. Aims 
The aims of this study on an unselected sample of patients with lung cancer in Southern 
Norway (the Agder counties) were to describe the various delays in the diagnostic process, a 
detailed smoking history, explore possible explanations for the high incidence of lung cancer 
in the Agder counties, and to give the main characteristics of the disease, including health 
related quality of life (HRQOL), mood disorders and mastery and interactions between these, 
to enquire upon patient satisfaction with treatment, and to describe the development of 
HRQOL and mood disorders from diagnosis to the end of first treatment cycle. 
2.2. Methods 
Unselected patients with newly diagnosed lung cancer, were prospectively included in this 
questionnaire-based study between June 14th, 2002 and June 13th, 2005 after written 
informed consent. Questionnaires regarding HRQOL (EORTC QLQ-C30 and LC13), mood 
disorders (HAD) and, mastery (SoC) were answered and details about smoking habits, 
symptoms and physician visits at referral and diagnosis were given. The development of 
EORTC and HAD scores and a specially made patient-satisfaction questionnaire after first 
treatment cycle were collected. 
2.3. Results 
Among 479 patients, 42% women, half of the patients were referred to a specialist in 
pulmonology within 3 weeks (median) of first seeing their doctor with symptoms of possible 
malignant pulmonary disease. 71% of patients were seen by a pulmonologist within 1 week 
of received referral, 52% were diagnosed and informed of their disease within 2 weeks of 
having received the referral letter, and 68% within 3 weeks. 62% started treatment within 1 
month of first contact with pulmonologist. 
95% had a history of smoking. 88% of ever-smokers reported having smoked primarily hand-
rolled cigarettes. Smokers of primarily hand-rolled cigarettes had smoked fewer cigarettes 
daily (15 versus 20) and less pack-years of tobacco (34 vs 42), but generally also had an 
earlier smoking debut, than smokers of primarily fabricated cigarettes. Smoking hand-rolled 
7cigarettes was more frequent than expected, and revealed an OR of 13 for developing lung 
cancer compared to fabricated cigarettes. 
Regarding HRQOL, fatigue and sore mouth were more pronounced in small cell lung cancer 
(SCLC) than in non-small cell lung cancer (NSCLC). There were no other differences in 
EORTC scores between histological groups. Patients in poor performance status (PS) 
reported worse functions and more symptoms, especially fatigue, dyspnoea, sleep disorders 
and appetite loss, than patients in PS 0-2. Every fourth patient had a HAD-score compatible 
with anxiety and/or depression, 17% with manifest anxiety and14% with depression. Mean 
SoC score was 58.3, i.e. 32% of patients scored ≤55, compatible with low mastery. Patients 
with mood disorders according to HAD reported considerably worse EORTC function scores. 
Reduced mastery/coping ability according to SoC was only weakly associated with anxiety 
and depression. HRQOL scores were poorer than reference values from selected EORTC 
chemotherapy and radiotherapy studies in lung cancer. 
After first treatment sequence patients reported worsening of nine HRQOL parameters. Only 
haemoptysis was improved. Patients in good PS receiving active treatment, reported 
worsening of physical and role functions after treatment, compared to stable functions in 
patients doing more poorly at baseline.  
Patients receiving surgery reported more dyspnoea and pain, and worse role and physical 
function, than the chemo- or radiation therapy group. Patients with NSCLC receiving 
radiation as primary treatment modality experienced more fatigue than patients receiving 
chemotherapy.  
Patients with mood disorders reported less anxiety and depression after first treatment. 
Those who were treated actively were definitely positive to repeat the same treatment 
sequence again (55 %), compared to only 15% among the patients receiving best supportive 
care.   
82.4. Conclusion 
This study revealed several potentials for improving the diagnostic process and shortening 
delays. The results were in alignment with Swedish and British recommendations in 52 to 
71% of cases. 
As nine out of ten ever smokers developing lung cancer in Agder reported having smoked 
primarily hand-rolled cigarettes, several results in our study may support the impression that 
the common use of hand-rolled cigarettes contributes to the high prevalence of lung cancer in 
the region, but official statistics on smoking patterns, brands and sales are scarce, leaving no 
possibilities for sound evaluation.  
In this unselected sample of patients with lung cancer, HRQOL was reported worse than in 
reference values from other studies of more selected groups, documenting a higher burden of 
illness than previously shown. Mood disorders were common and associated with reduced 
functions and increased symptoms compared to those without anxiety or depression.  
The changes in HRQOL after first treatment modality are mostly correlated with disease 
progression and side-effects. Patients with mood disorders seem to be a group of patients 
needing more information and closer follow-up to reduce side-effects of treatment in future. 
We also find a need for developing easier tools for the measurement of HRQOL in unselected 
patient populations. 
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5. Introduction 
5.1. Lung cancer  
5.1.1. Definition and incidence 
Lung cancer is the common term for bronchial carcinoma, including small-cell lung cancer 
(SCLC) and non-small-cell lung cancer (NSCLC) with histological subtypes(1;2) and is the 
most frequent cancer type world wide today, genders seen together, accounting for 
approximately 1.5 million new cases in 2007, or 12% of total cancer diagnoses(3).  
The smoking of tobacco products is closely linked to the incidence of lung cancer(4) and for 
the same reason the incidence is now increasing rapidly among women world wide, as 
experienced in North America and Scandinavia the last 50 years(5;6).  
The incidence of lung cancer in Norway is still increasing, and mortality due to lung cancer is 
increasing sharply for women, while stabilizing for men. Lung cancer is the most important 
cause of cancer related deaths in Norway today, both genders seen together(6). 
The Agder counties have, for partly unknown reasons, a higher incidence of lung cancer than 
the national average (figure 1).  
Figure 1. Relative risk of cancer in the lower airways in counties.  
(From the Norwegian Cancer Registry, 2002) 
Women in Eastern Agder accounted for an almost  200% increase in lung cancer incidence 
from 1985 to 1995(7) and by 2007, women in Western Agder had the highest age-adjusted 
incidence-rates in Norway, 31.4, compared to country-mean of 23.0(6) . The reason for this is 
not understood. 
Menn Menn Menn
kvinner 
menn 
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Each year about 170 new cases of lung cancer are diagnosed in Agder. The incidence is 
highest among both genders in those townships holding large numbers of smokers (smoking 
has traditionally been more common in urban areas compared to rural(8;9), and in 
Kristiansand in particular(7)). Kristiansand has a high incidence of 45-52 new lung cancers 
per 100 000 inhabitants per year(10). Agder holds several industrial agencies with previously 
high nickel and asbestos exposures, but traditionally employed few women and has formerly 
been evaluated not to explain the high incidence among females(7). 
5.1.2. Treatment 
5-year survival in lung cancer is 10-13%, and has been more or less the same the last 40 
years(2). However, the population has changed in this period, with an increased proportion of 
elderly, -in it self an important prognostic factor for long time survival. Besides this, the 
recent survival figures may hide a small reduction in post-operative mortality, which has been 
somewhat reduced due to improved post-operative care. Further, improved pre-operative 
staging has raised the adequacy of the treatment options recommended(2;11).  
Surgery is the main treatment that can heal lung cancer. 30% of patients are considered 
operable at the time of diagnosis in the western world today(12). In Norway this number has 
been lower. The Norwegian Cancer Registry showed that only 17% of patients with lung 
cancer were treated surgically in Norway 1991-95(13). Even among patients with localized 
disease only ¼ of the patients were operated. The reason why so few patients were sent to 
surgery is poorly documented. 
After the opening of Centre for Treatment of Cancer (SfK) at Sørlandet Sykehus Kristiansand 
(SSK) in 2002, the pulmonary department of SSK had local access to all common treatments 
for lung cancer, including radiation and surgery.  
Thus, we wished to broaden our competence on the area, and also to get a better overview of 
our results in the treatment of lung cancer. Surprisingly enough, no Norwegian hospitals had, 
as the study was initiated, a full overview of their results in the treatments of lung cancer.  
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5.1.3. Side effects of disease and treatment 
As more patients are offered palliative, non-curative treatment for lung cancer today than 20 
years ago, possible side-effects of treatment can be more frequently encountered now than 
previously. Patients and their relatives seem to react very differently to side-effects, some 
regretting that they agreed to receive treatment. To the clinician, it seems important to 
understand why some patients develop and/or experience more side effects than others, in 
order to improve the guidance of therapy and information. Patients suffering from lung 
cancer are shown to have more symptoms and distress compared to other cancer patients (14-
17). Symptoms are associated with reduced quality of life (QOL) (18).  
5.1.4. Diagnostics and delays 
Awaiting information about the serious diagnosis of lung cancer is a strenuous situation for 
the patient and relatives. The delay from first contact with health workers and hospital to 
information and treatment should be as short as possible. The Norwegian Society of Thoracic 
Surgery has recently defined the acceptable delay from referral from diagnosing 
hospital/department to date of surgery as within 2 months (Steinar Solberg, The Norwegian 
National Hospital; personal communication, February 2008). Even though such delays may 
be medically and technically justifiable, each day of waiting seems unacceptable and 
associated with anxiety and concern for the patient. Thus, cancer patients should be admitted, 
examined and treated as rapidly as possible. 
Wishing to evaluate whether lung cancer is diagnosed and treated within acceptable limits, 
there are no specific national guidelines for the diagnostic process. Thus, mapping out the 
local delays and comparing our results to international guidelines became an important part of 
the study. Comparable time limits considered were guidelines from the British Thoracic 
Society(19) and the Swedish Lung Cancer Group(20;21). 
5.2. Tobacco smoking and other risk factors 
Doll and Hill proved the association between smoking and lung cancer in 1950(22;23) and 
established the dose-response relationship, further enhanced by an early smoking 
debut(24;25). Today we know that more than 85% of lung cancers are caused by tobacco 
smoking(26;27). More than one third of the world’s population was stipulated to be smoking 
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in 2000, and new data show that the amount is still increasing(28), especially in densely 
populated regions such as China and India(27;29). Women seem to be two to three times 
more at risk to develop lung cancer when smoking the same amount of tobacco as men 
(30;31). Since the mean age for smoking debut today is lower for both genders than in 
previous decades, and mostly so for women(32;33), both the percentage associated with 
smoking and the crude incidence of lung cancer may increase in the near future(34). Hand-
rolled cigarettes (HRC), so-called pack-tobacco, may increase this risk by a factor of two 
compared to factory-made filter cigarettes (FC) (4;35). 
Norway is different from the rest of the Western world, since one third of the smoking 
population is using hand-rolled cigarettes(4). In a recent survey from 2003, 44 and 28 percent 
of smoking Norwegian men and women, respectively, reported using HRC only(36). HRC 
have until recently been far less expensive than factory-made cigarettes in Norway, and by 
2006 one third of all tobacco sold was pack-tobacco (personal communication; Rita Lindbak, 
Dept. of Health). By comparison, pack-tobacco sold two and a half times more than FC in 
Norway in 1973. Sales statistics for other western countries concerning pack-tobacco are 
roughly non-existent, as the consumption has decreased distinctly since the 1950s(4). 
Many studies on tobacco related diseases report whether the patient was smoking or not, but 
detailed smoking habits and history are scarce.  Other reports on populations of lung cancer 
do not mention smoking at all(37). Alexandersen found that the majority (not further 
described) of lung cancer patients treated in Bodø reported smoking pack tobacco(38).  
Tobacco smoking is the most important risk factor for developing lung cancer, but 
occupational exposure to nickel and asbestos might contribute to the high incidence of lung 
cancer in Agder, though hardly for women(7). The coastal population has a long history of 
sailors, often exposed to asbestos during work in the engine room. Parallel to this they had 
easy access to inexpensive tobacco abroad.  
Little is known concerning domestic exposure to radon. Studies have shown conflicting 
results(39-42). Radon emittance is local, and associated with geology and building structure. 
Some of the highest radon concentrations in Norway have been found in Telemark county, 
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neighbouring on Aust-Agder, while very few local measurements have been performed in 
Agder(43).  
As tobacco smoking is considered the main reason behind most cases of lung cancer, but few 
details on tobacco use in this patient group are public, we considered mapping out the details 
of consumption a primary objective. 
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6. Aims of the study 
Our intention with this study was, in an unselected sample of patients with newly diagnosed 
lung cancer in the Agder counties 
• To describe the delays in the diagnostic process of lung cancer, and whether these are 
within acceptable time limits  
• To give the main characteristics of the disease, including 
o Health related quality of life (HRQOL) 
o Mood disorders and 
o Mastery and 
o Interactions between these 
• To enquire upon patient satisfaction with treatment  
• To describe a detailed smoking history and explore possible explanations for the high 
incidence of lung cancer in the Agder counties 
• To describe the development of HRQOL and mood disorders from diagnosis to the end of 
first treatment cycle 
Since no other Norwegian hospitals could describe detailed results of treatment offered to an 
unselected group of patients with primary lung cancer, this material was considered important 
for future comparisons between centres. Further, the evaluation of HRQOL, mood disorders, 
mastery and patient satisfaction in such an unselected sample was not reported before the 
study was started. 
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7. Design and methods 
7.1. Study title 
CAPPA is abbreviation for CAncer Pulmonis På Agder (i.e. lung cancer in the Agder 
counties), used as a working title for the study. 
7.2. Study design 
A prospective, continuous, questionnaire-based study on all patients >18 years hospitalised or 
treated in an out-patient clinic in the hospitals in Eastern (Sørlandet Hospital Arendal) – and 
Western (Sørlandet Hospital Kristiansand) Agder with a newly diagnosed lung cancer 
between June 14, 2002 and June 13, 2005.  
The patients received oral and written information and were requested to participate in the 
project. Inclusion was voluntary, with the possibility of withdrawing during the study for any 
reason, without this influencing further treatment at the hospital. Written consent was 
collected before inclusion. 479 patients were enrolled; the inclusion rate was 97% (figure 2).  
Figure 2 Inclusion and response rate to questionnaires at baseline in an unselected population of patients 
with primary lung cancer in Southern Norway 
Additionally to answering questionnaires, the participants gave allowance to the collection of 
data, such as histological subtype and dates of contact and diagnosis, from the hospital 
records. 
Eligible 492 
Moved 2/ 
Refused 6/ 
Did not speak language 1
Included 479 
Faulty diagnosis; 
Malign.mesothelioma 2/ 
TBC1 /breast cancer 1 
                     Response rate 
EORTC              HAD                      SoC 
 n= 303             n= 290                  n= 251 
  63%                  61%                      52%  
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In cases of missing answers, patients were contacted by telephone or mail twice. Baseline 
response was used for further QOL-analyses if answered within 14 days of information about 
the diagnosis. However, a few responses from ECOG Performance Status 0-1 patients are 
missing because they were rapidly admitted for surgical treatment without having answered 
the baseline questionnaires. Other responses failed because patients in PS 3-4 were too sick to 
answer questionnaires, but have agreed to enrolment and data collection from the hospital 
records. 
7.3 Methods 
7.3.1 Health related quality of life (HRQOL) 
Quality of life is becoming more important as a hard end point in the research on 
cancer(44;45). Wyller maintains that QOL is a broad definition, that should be evaluated and 
described more thoroughly, especially seen from the patient’s point of view(46). According to 
Campbell a general definition of quality of life is “a person’s subjective feeling of well being 
as a result of his experience from life as a whole”(47). By narrowing the QOL description to 
those parts that are primarily related to health, the conception of health related QOL has 
emerged(48). There are many validated questionnaires on HRQOL for studies in patients with 
lung cancer(49-59). To be told that one suffers from cancer has large influence on people’s 
life. Thus it is utmost important that a questionnaire that is to measure changes in quality of 
life during cancer, measures a broad spectrum of factors, such as physical activity, 
psychological well-being, social status and symptoms(60). 
The European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 with 
the lung cancer specific supplement LC13(52) is well known, valid and reliable and measures 
the most common parameters(61-63). It is also translated to Norwegian, and has been used in 
many clinical studies. It is intended for the patient to answer personally(64;65).  
The QLQ-C30 consists of 5 function scales (physical, role, emotional, cognitive and social), 
one global QOL scale, three symptom scales (pain, fatigue and nausea and vomiting), and 
several single symptom assessments. The LC13 holds additional, lung cancer specific 
symptoms associated with the disease and treatments. (Appendix I) 
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Such registrations can give important knowledge on how the different treatment modalities 
and symptoms influence every day among lung cancer patients.  
Scoring has been performed according to scoring procedure(66), linearly transformed into a 
score from zero to 100. Among the function and global QOL scales, a high score represents a 
high level of functioning, whereas a high symptom score equals a high symptom load. 
7.3.2 Anxiety and Depression  
Emotional disturbances may result from the serious diagnosis of lung cancer, but pre-existing 
disease may also influence delays in the diagnostic process, as well as the experience of side 
effects from treatment. Previous studies have shown correlations between mood disorders and 
QOL(67), and more recently, after the start of this study, between mood disorders and coping 
abilities in lung cancer patients receiving specific treatments(44;68).  
The Hospital Anxiety and Depression (HAD) questionnaire consists of 14 items of which half 
and half assess anxiety and depression, respectively. Each sub-score may vary from 0 to 21 
points. The questionnaire has been widely validated and reliability tested (69;70). Scoring >8 
points are defined as possible/borderline psychiatric disease, while >11 points indicate 
clinical depression or anxiety associated neurosis(70), as reported in several other 
studies(67;69). (Appendix II) 
7.3.3 Mastery 
People’s life experience influences their perception of symptoms and illness, and their 
susceptibility to information. 
Most of the experiences contributing to an individual’s mastery are, according to 
Antonovsky(71), at large collected during childhood and early adulthood, and stabilise 
around the age of 30. 
Dalgard et al(72) recently found that persons with a strong sense of mastery, as measured 
with the SoC, had lower psychological distress, judged by questions about depression, anxiety 
and psychosomatic symptoms. They also found an association between level of education and 
psychological distress. 
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The Sense of Coherence questionnaire (SoC) has been proven valid and reliable(71), and is 
widely used throughout the world(73;74), also in Norway(75). The 13 items are valued from 
1 (weak coping ability) to 7 (strong coping ability). Total score results from summing up raw 
scores, and can range from 13 to 91. High values indicate high coping abilities. (Appendix 
III) Based on findings from studies on other patient groups(76;77), we set an arbitrary cut-off 
value at 55, defining scores equal or below 55 as low mastery.  
7.3.4 Delays  
According to the definitions of delays in the guidelines from the British Thoracic Society(19) 
and the Swedish Lung Cancer Group(20;21) the delays in the diagnostic process used in this 
study were defined as: 
• Patient delay = Time from first symptom to first personal contact with doctor  
• GP delay = Time from first contact with general practitioner (GP) to date on written referral  
• Referral delay = Time from dated referral receipt to first contact with pulmonary consultant  
• Specialist delay = Time from first contact with pulmonary consultant to dated diagnostic 
histology/cytology  
• Informed diagnostic delay = Time from decision of doing a diagnostic procedure to 
informing patient of diagnosis. Thus, time from decision was stated as the date of referral 
receipt + 2 days, which is considered the mean time used (including weekends and public 
holidays) before a decision of diagnostic procedure/sequence was done  
• Hospital delay = Time from first contact with pulmonary consultant to start of treatment  
• Total delay = Time from first symptom to start of treatment 
7.3.5 Patient satisfaction 
Patients with symptoms of serious illness are worried and in need of empathy and repeated 
information. Patients have various reasons for reacting differently to information as well as to 
treatment-related side-effects. 
A questionnaire concerning patient satisfaction with information and treatment from the 
medical institution and its employees was constructed on the basis of a questionnaire used for 
patient satisfaction validations in Norway, as developed by Centre for Health Care 
Evaluations(78). The pre-printed alternatives for answering were ranged from 1 to 5 or 1-7, 
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ranging from “very unsatisfactory” to “highly satisfactory”, and “absolutely not” to” 
definitely so”, concerning the last two questions. (Appendix IV) Total sum attainable, 
omitting questions 10 to 13, which were treatment specific, was 60. This questionnaire has 
been translated to English for the purpose of this thesis only (Appendix IVb). 
7.3.6 Smoking habits and exposure to lung toxic substances 
Concerning exposure to potential lung toxic substances, and knowing that Norwegians have a 
somewhat different tobacco consumption than other countries, a detailed questionnaire was 
constructed especially for the purpose of this study, asking about smoking, occupational 
exposures and comorbidities (Appendix V,VI). Questions were partly based on a previously 
used questionnaire from the Norwegian Directorate of Health(79), but were developed further 
in order to acquire more detailed data. Patients were asked about time of smoking debut, 
which brand and kind of tobacco they had smoked primarily, i.e. at least 50% or more, and 
which percentage of their consumption had been pack tobacco and fabricated cigarettes, 
respectively.  
Patients were asked about the longest duration of education and main occupation, divided 
into groups categorizing according to expected exposure to lung toxic substances, such as 
nickel, asbestos and dust. 
Measuring domestic radon in the homes of patients with diagnosed lung cancer was originally 
planned as part of this study, but we ran into legal complications, as we could not do 
measurements in people’s homes without informing them of the results, and authorities 
insisted that we must offer economic support in cases of increased radon measurements, for 
venting or rebuilding, if detected. 
Drinking water was also considered a potential source of toxic exposure, but research 
revealed more than 90 different water sources supplying the area, in addition to single local 
wells. Thus, analyzing these sources in regard of traces of heavy metals and low pH would be 
very complicated, and, according to large epidemiological findings(27), a very small 
contributing reason, if any. 
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7.4 Statistical analysis 
Statistical analyses were performed with SPSS 13-16 (Statistical Package for Social Sciences, 
SPSS Inc. Chicago, USA). 
Regarding the number of patients in the study, no a priori power calculation of study size was 
performed. We considered that the inclusion of approximately 400 patients during a 3-year 
period would be adequate for sound analyses of several important parameters. We also 
expected this number of patients to be adequate for forthcoming survival analyses. 
Continuous data with normal distribution were analyzed with Student’s t-test, and presented 
with mean and standard deviation (SD), as central tendency and dispersion measure, 
respectively. Correspondingly, Mann-Whitney-U-test was used if distribution of data was 
skewed and presented with median and inter-quartile range (25.th and 75.th percentiles), 
respectively. Pearson’s Chi Square test was used for categorical data comparing percentages. 
Because our data on HRQOL proved largely non-linear, while most results from comparable 
studies were presented using t-test, analyses were performed both ways(66;80;81).  
Simple and multiple logistic regression analyses were performed where necessary, using 
backward, stepwise conditional methods.  
In cases of missing answers to EORTC questionnaires, a mean of related items was 
calculated and substituted, according to scoring instructions, in cases of function or symptom 
scales based on several answers if at least half of the items had been answered(66). Missing 
single answers were not substituted. 
Differences in analyses were considered significant with a p of less than 0.05, in two-sided 
tests. According to recent recommendations(82), changes in HRQOL-parameters should be 
considered clinically significant if ten or more percent change towards improvement or 
worsening. 
23
Because of missing comparable data on smokers of hand-rolled cigarettes in the region, a 
crude odds ratio (OR) for smokers of hand rolled cigarettes (HRC) was calculated, assuming 
an average Norwegian percentage of healthy smokers of HRC in the region. 
The questions about effects and side-effects of treatment were omitted from the patient 
satisfaction analyses, as comparison to the group receiving BSC only would otherwise not be 
possible. Total sum was compared between groups, using independent samples t-test.  
7.5 Ethics 
The study was approved by the Regional Ethics Committee on Research and the National 
Data Supervision Centre, and is performed in accordance with the Helsinki Declaration. 
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8. Synopsis of papers I-IV 
8.1 CAPPA – baseline characteristics of patients included in the 
study 
42% of patients were female, mean age at the time of diagnosis was 68 years for both 
genders.  
21% had SCLC, one third had adenocarcinoma. 72% of patients were in TNM stages IIIb or 
IV, thus beyond a curable condition.  
For the group as a whole, 16% received surgery as primary treatment option (but 23% of 
patients with NSCLC), one third chemotherapy, one third supportive care only (table 1). 
Table 1 Baseline characteristics of an unselected sample of 
patients with primary lung cancer in Southern Norway 
 N= 479 
Gender; male, % 58 
Age, mean (SD) 68 (11) 
Performance status ECOG, %
- 0-2 
- 3-4 
66 
34 
Stage TNM, %
- 1a-3a 
- 3b-4 
28 
72 
Histology, %
- SCLC 
- NSCLC 
- Unknown 
21 
70 
9 
Primary treatment, %
- Surgery 
- Radiation 
- Chemotherapy 
- Supportive Care 
16 
19 
31 
34 
8.2 Paper I 
52% of patients contacted doctor within 3 weeks of first symptom of disease, and 49% were 
referred to specialist within 3 weeks of first contact with general practitioner. 71% of patients 
with lung cancer were evaluated by specialist in pulmonology within 1 week, not fulfilling 
the British or the Swedish recommendations of 100 or 80%, respectively. Correspondingly, 
informed diagnostic delay was within 2 weeks in 52%, and within 3 weeks in 68% of cases. 
62% started treatment within 1 month of first contact with pulmonologist, whereas the 
Swedes suggest that 80% should. 
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Patients in advanced tumour stage had shorter delays than those with potentially operable 
disease, with smaller tumour masses, giving less symptoms and possibly more difficult to 
biopsy. Female gender, as well as SCLC histology, had shorter specialist- and hospital delays, 
respectively. Whether chest X-ray was performed before referral to the pulmonary consultant 
or not, did not influence the delay from GP to final diagnosis. 
8.3 Paper II 
63% of patients answered the EORTC questionnaire at the time of diagnosis. Those not 
answering, were older, had poorer performance status and there were more patients suffering 
from SCLC-Extensive Disease than among the responders. 
Patients with SCLC reported more fatigue and sore mouth compared to those with NSCLC, 
and more depression (p≤0.03). Besides this, there were no differences in EORTC scores 
between histological groups. Compared with reference material from EORTC databases(83) 
from chemotherapy and radiotherapy studies, the results from CAPPA were considerably 
worse, especially concerning role, social and physical functions, global QOL, dyspnoea, 
diarrhoea and fatigue, documenting a higher burden of illness/symptoms than documented in 
the literature concerning treatment for the disease. Poor emotional function was associated 
with anxiety and depression (p<0.0001), and physical- and role functions were worse in cases 
of poor performance status (p<0.0001). 
According to HAD, 17% of patients scored compatible with anxiety and 14% with depression 
and one in four consistent with manifest anxiety and/or depression. Cases of anxiety and 
depression seemed closely related, with a ten times increased OR for depression if concurrent 
anxiety compared to non-existing anxiety, as measured by HAD.  
Mean SoC score was 58.3. Mastery, measured by SoC, was significantly lower in patients 
with mood disorders than without. 
According to these findings clinicians might need to spend more time on information, and be 
more devoted to upcoming questions from patients with lung cancer and mood disorders.  
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8.4 Paper III 
81% of patients responded to the smoking questionnaires. 95% of patients in CAPPA had a 
smoking history, while 55% were current smokers.  
21 patients (4%) had never smoked, but one-third of these reported living with another 
smoker for at least ten years. The never-smokers were 7 years older than ever-smokers when 
lung cancer was diagnosed. There was a considerable incidence of adenocarcinoma among 
the never-smokers (62% vs 33%), and 3 patients had features of bronchioloalveolar 
carcinoma (BAC).  
88% of ever-smokers reported having smoked primarily hand-rolled cigarettes (HRC). These 
had more frequently started smoking at a young age, 54% before age 17, compared with 37% 
among smokers of fabricated cigarettes (FC), p=0.04, χ²-test. 
Very few smokers reported using filter when smoking, 21 patients totally, whereof 9 smoking 
FC. Because of low numbers, further analyses were not performed. 
Smokers of HRC had smoked in average 5 years longer than those smoking fabricated 
cigarettes as the disease was diagnosed. However, they had smoked fewer cigarettes per day 
(15) and consumed significantly less pack-years of tobacco (35) than those smoking 
fabricated cigarettes (20 and 42, p<0.0001 and p=0.021, respectively) (table 2). 
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Table 2 Tobacco consumption in smokers of hand-rolled cigarettes compared with fabricated cigarettes in 
patients with newly diagnosed lung cancer in Agder. [Student’s t-test; Mean (SD)] 
 Hand-rolled cigarettes
(n=284) 
Fabricated cigarettes
(n=39) 
p (95% CI) 
Age starting 17 (4) 19 (3) 0.07 (-0.1 to 3) 
Years smoking 46 (10) 41 (14) 0.009 (1 to 9) 
Pack-years 34 (18) 42 (25) 0.021 (-14 to -1) 
Average 
cigarettes/day 
15 (7) 20 (10) 0.0001 (-8 to -2) 
Maximum 
cigarettes/day 
20 (12) 26 (13) 0.013 (-9 to -1) 
The use of hand-rolled cigarettes was considerably more frequent in this study than expected 
from official sales statistics. Assuming a similar smoking pattern as reported in national 
statistics, smoking hand-rolled cigarettes revealed an OR of 13 for developing lung cancer 
compared to smoking fabricated cigarettes. 
The use of hand-rolled cigarettes among people developing lung cancer in Southern Norway 
thus is more prevalent than known from official sales statistics. The results may indicate that 
smokers of hand-rolled cigarettes seem to have a greatly increased risk for lung cancer 
compared to smokers of fabricated cigarettes.  
8.5 Paper IV 
87% of patients responding to the EORTC QLQ C30-questionnaire at baseline, and still alive, 
answered the follow-up questionnaires after primary treatment sequence. As a group, they 
reported significant worsening of physical function, role function, fatigue, pain, constipation, 
financial troubles, dysphagia, dyspnoea and alopecia (all p’s <0.02), but less haemoptysis. 
Among patients with NSCLC each treatment group reported worsening of parameters 
especially connected to treatment modality, as operated patients had significantly more 
dyspnoea and worse role function compared with those receiving chemo- or radiotherapy. 
Receiving radiation therapy was associated with more fatigue than treatment with 
chemotherapy (p=0.01) for changes of at least 10%, which is defined as clinically significant.  
Patients with NSCLC receiving active treatment and in good ECOG PS (0-1) experienced 
worsening of physical(mean -15, SD24) and role function (-14 (42)) after treatment, while 
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those in poorer PS (2) reported  improved emotional (15 (34))and role function (13 (38), 
p’s<0.05). 
Patients with anxiety and / or depression at baseline reported reduced emotional disturbances 
after treatment.  
One third of patients with lung cancer scored below 55, i.e. compatible with low mastery. 
This group had poorer physical, emotional, social and cognitive functions and global QoL-
score at baseline (all p’s <0.03), and higher anxiety and depression scores (p’s<0.02) than 
those with “normal mastery” above 55.  
Patients receiving active treatments reported more total satisfaction with treatment received, 
41 mean, SD 8, than those receiving BSC alone, 33(9), (p<0.0001).  84% of patients 
receiving surgery as primary treatment would definitely or probably repeat this, compared to 
79% of patients receiving chemo- or radiotherapy, and 65% of those having BSC only. 
Similarly, 91% of patients receiving surgery would recommend this to others, compared to 
56% of the BSC-group (p<0.0001), figure 3. 55% of patients receiving active treatment 
would definitely repeat, only 15% in the BSC-group.
Figure3. Patients’ willingness to repeat or to recommend same treatment 
modality in case of new, similar diagnosis 
65
79 79 84
56
83 86
91
0
20
40
60
80
100
BSC Radiation Chemotherapy Surgery
%
Repeat treatment Recommend treatment
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9 General discussion 
9.1 Methodological considerations 
9.1.1 General 
As clinicians taking care of all patients with lung cancer, we found it essential to include all 
patients in the study, not only those eligible for tumour-reducing treatments. However, it is a 
problem to get adequate response to questionnaires from those most diseased from their lung 
cancer, thus increasing the possibility of a somewhat biased result, missing more responses 
from the patients in poorest PS. We believe our results conveying HRQOL, mood disorders 
and mastery in an unselected population of lung cancer patients are closer to “the real world” 
of daily clinic than most published, treatment-related studies. We hope this can add important 
data for comparisons and basics for treatment-decisions in the large body of patients whom 
are unsuited for partaking in studies run by the pharmaceutical industry, or whom are not 
interested in palliation chemo- or radiotherapy.  
9.1.2 Information bias 
By introducing a study evaluating the process of diagnostics of a group of patients, there is a 
risk that knowledge thereof might increase the attention upon the evaluated process, thus 
risking a certain shortening of some of the measured delays, as involved colleagues know that 
the time is being registered, and more attention on symptoms and feelings regarding quality 
of life. However, there are no specific reasons why information bias in this study should be 
especially troublesome compared to other comparable studies. 
9.1.3 Selection bias 
63% of included patients responded to questionnaires at baseline within the defined time limit 
of 14 days after diagnosis. Compared to large treatment-related studies selecting a small 
group of patients with lung cancer in performance status 0-1, this seems like a poor result. 
However, we have intended to evaluate the entire patient population, as we do in the general 
lung cancer clinic. The patients being in the poorest performance status at baseline are the 
ones least able to respond to questionnaires. Nevertheless, many have answered, and our 
results are thus different from “comparable” studies(52;84), even if not all patients have 
replied.  
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87% of patients answering the HRQOL questionnaires within defined time limit at baseline 
and still alive responded to the follow-up questionnaires. We find this a good compliance, but 
realize, of course, that the most diseased patients are missing, introducing a selection bias 
here, due to deaths and increased morbidity. However, literature shows a connection between 
deteriorating PS and increasing symptoms(52). We found that patients in poor performance 
status (PS3-4) had worse functions and more symptoms at baseline than those in PS 0-2. We 
thus believe that the non-responders would have reported similarly poor results of HRQOL, 
as most of them were in PS 3-4, thus making the total scores for the whole unselected patient 
population even worse. 
9.1.4 Recollection bias 
Patients were asked to report their smoking history. This is a retrospective registration. 
People seldom report more than actual smoking over time, and often less (85). It is unlikely 
that smokers of hand-rolled cigarettes should report differently compared to smokers of 
fabricated cigarettes. If the results are biased, actual use of tobacco products should probably 
be higher for both groups. 
Concerning amount smoked, we asked about average number of cigarettes and packs of 
tobacco, and the reported numbers correlated well, assuming that 50 grams tobacco make 50 
cigarettes. 
9.2 Discussion of some of the main results   
9.2.1 Delays 
Having no national recommendations on acceptable delays in the diagnostic process of lung 
cancer, it seemed important to map out our local process and concentrate upon possible areas 
of improvement. Although we found the British recommendations hardly suitable for general 
practice, recommending 100% of patients diagnosed and informed within 2 weeks, they 
suggest the ideal situation, for which we should aim. Our hospitals diagnosed within the 
British recommendations in 52% of cases, which is not good enough, by far. However, the 
delays in our study were within those of the Swedish Lung Cancer Group in 62-71%.  
Acquiring good biopsies without performing hazardous examinations sometimes takes time, 
but performed by trained physicians and within a planned schedule, the gross body of patients 
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should have their diagnosis and plan of treatment within 3 weeks of first meeting the 
pulmonologist. Our out-patient clinic has since the time of the study continuously remodelled 
the diagnostic work-up of suspected lung cancer patients in order to increase efficiency and 
shorten delays where possible. However, through more accurate diagnostic methods recently 
available, such as PET-CT and EBUS, where patients now are referred to regional central 
hospitals due to political decisions and prioritized allocation of resources, the delays in the 
diagnostic processes are again increasing. 
9.2.2 Choice of and response rates to questionnaires  
9.2.2.1 HRQOL questionnaires 
We could have chosen another HRQOL-questionnaire, but the EORTC form was well tested, 
translated and used in many studies in Norway and world-wide, and was thus evaluated as the 
best choice.  
Through the study, we have done painful experiences concerning our choice of the EORTC-
questionnaires, which proved less suitable for an unselected patient population, although 
originally described as “for assessing the HRQOL of cancer patients participating in 
international clinical trials”(66). The EORTC QLQ-C30 is the most common cancer-related 
HRQOL questionnaire used in the Nordic countries. However, the much used, validated and 
tested EORTC questionnaires QLQ-C30 and LC13 met basical statistical challenges in this 
real life study on an unselected patient population due to a much larger dispersion of HRQOL 
data with all patients included, i.e. also many in poor performance status, compared to what is 
common in treatment related trials, where only patients in PS 0-1 and sometimes PS 2 are 
included. The recommended statistics to be used with the EORTC questionnaires are t-tests, 
due to normal distribution and thereby less dispersion of data in more selected samples of 
patients in treatment related studies. In this situation, to compare our results with previous 
publications, we also performed the analyses with the recommended t-tests. However, based 
on purely statistical assumptions, the Mann Whitney U (MWU) test could several times have 
been used instead. Thus, the EORTC results were also tested with MWU tests when statistical 
assumptions were fulfilled, resulting in only minor and less important deviations from what is 
concluded in the articles. 
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With this experience, we judge the EORTC questionnaires to be definitely less suitable for 
real life studies and see the need for simpler and more suitable questionnaires for real life 
settings. This could be a topic for future research, performed on an unselected patient 
population, as most clinicians meet in their clinics, rather than a highly selected group fit for 
receiving new pharmaceuticals.  
9.2.2.2 Response rates 
Many questionnaires have been invented and tested in order to evaluate HRQOL, which is 
increasingly utilized in cancer studies(86;87). Mills et al found that lung cancer patients 
registering QOL weekly reported that it had a negative impact on their lives compared to 
those who did not(88). Health care professionals should be trained to incorporate patient-
QOL-changes into daily practice to make the response “worth-while” and make the patient 
feel “rewarded” for responding to questionnaires(88). It is difficult to find the right frequency 
of recording HRQOL to detect meaningful changes without losing patients before next 
response, parallel to not overloading the patients with forms, making them stressed by the 
work-load and putting too much attention to their disease and possible changes in symptoms. 
Sundstrøm concluded that it is most important to ensure good compliance on HRQOL 
questionnaires at baseline(81). 
Crude response rate in our study was better than shown in figure 2 (page 13), but some 
patients needed more time before submitting their response, others received the 
questionnaires late because of concurrent procedures or treatment. 
In an unselected patient population suffering from a progressive disease with poor prognosis, 
such as lung cancer, and concurrently associated with high comorbidity, it is difficult to make 
all patients give a written response within 14 days of receiving such a serious diagnosis. 
Knowing that this has been a problem in prior studies, as well (84), we repeatedly contacted 
the patients by mail and/or telephone, but some times responses came later than desired and 
the answers had to be discarded from further analyses. As the patients became more 
acquainted with the study, responses were better, and thus the follow-up rate was better 
among those responding within the baseline time-limit and still alive (87%, paper IV). There 
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are different ways of substituting missing answers, but we have chosen not to impute whole 
series of answers in cases of non-responders.  The main non-responding population at 
baseline was too ill to answer, and our hypothesis is that the main results on HRQOL would 
have been worse if this group had been able to respond. This assumption is supported by 
several others, suggesting that measuring performance status may serve as a surrogate marker 
of QOL(89;90). 
We still believe the response rates in this study are high standards for an unselected 
population of primary lung cancer, and that these results mirror actual findings obtainable in 
clinical practice. 
9.2.2.3 Changes in HRQOL 
The reported changes in HRQOL from the time of diagnosis to the end of first treatment 
cycle are considered treatment-specific, revealing no really surprising results for the trained 
clinician. However, the characterisation of these parameter changes in an unselected sample 
of patients are again considered important in an attempt to describe real life settings when 
lung cancer is treated. These results should therefore be applicable for many lung physicians. 
Surgery has recently been described to decrease functional scales(80;91), but only for some 
months. In a survey on lung cancer patients treated with radiation, Langendijk found lasting 
deterioration in functional scores, while fatigue improved shortly after ended treatment, only 
to increase again after 3 months(91).  
Post-treatment response to HRQOL questionnaires is difficult to collect systematically 
enough for proper comparisons between groups. Patients receiving BSC only are at large in 
poor performance status at baseline, with poorer survival than those receiving active 
treatments. The number of patients fit enough for adequate responses to questionnairres falls 
quickly. We considered collecting post-treatment response 3-4 weeks after ended treatment to 
be adequate, to assess transient treatment effects also among those patients deteriorating 
rapidly after finishing a treatment cycle. However, responses from patients shortly after 
radiotherapy or surgery are probably different from responses collected 6-8 weeks 
later(80;91;92), an interval often followed in the out-patient clinic.  A prolonged response 
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interval after radiation therapy and surgery may have improved the HRQOL scores somehwat 
in this group, if chosen. 
9.2.2.4 Patient satisfaction 
Patient satisfaction with treatment received, additionally to treatment effects and survival, are 
measures on quality of care. In order to further scrutinize the reasons behind some patients 
and relatives expressing regrets concerning treatment received or not received, two questions 
were raised after first treatment, or, if BSC alone, at first control, asking if they would have 
accepted the same treatment again, knowing what was ahead, if receiving the diagnosis now. 
Similarly, if they would recommend their treatment sequence to close peers. Of course, 
knowing that the responses will be known within the treating institution may influence the 
response, making the patient less critical than if asked by an independent part. However, the 
questionnaire was handed out or mailed by a study nurse or –physician, mostly not 
responsible for the treatment. Not surprisingly, patients receiving no active tumour-directed 
treatments were the least satisfied. Thus, the clinicians need to improve our skills at 
explaining seriously ill lung cancer patients why treatment beyond pure symptomatic care in 
some cases means more side effects than gains, as the patients express doubts concerning 
whether they have been offered the best treatment available for their disease.  
9.2.3 Smoking hand-rolled cigarettes 
9.2.3.1 Registering smoking habits 
We were surprised that 88% of ever-smokers reported smoking primarily hand-rolled 
cigarettes, although it confirmed the general impression from working in the clinic. Because 
of missing data on type of tobacco smoked in the general Norwegian population, basis for 
comparison is missing. There has previously been local tobacco production in Kristiansand, 
with two processing plants. Several patients have reported receiving packs of local tobacco 
brands from relatives for Christmas during adolescence, thus indicating recruitment of young 
smokers. Neither tobacco companies nor their marketing agency have been cooperative upon 
our requests concerning local sales or statistics on type or brand of tobacco products over 
time in the region. National statistics have done very narrow research on smoking, mostly 
limited to: Are you smoking? with the ticking off on “yes” or “no” and user age.  
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Our questioning, asking people who have developed a serious, mostly incurable disease, 
about detailed smoking habits, which is known as the main reason for developing lung 
cancer, is debatable. Patients developing lung cancer who continue smoking, have been 
reported to have poorer QOL than former smokers(93-95), possibly because of bad 
conscience and negative stigmata concerning their smoking. However, none of the 
participants of this study have offered any negative comments to the detailed questioning. 
Registrations of smoking habits have to be retrospective, based on the patient’s memory. We 
asked about which kind of cigarettes and tobacco the smokers had used the most, and which 
percentage had been HRC, FC etc. For the convenience of analyses, we have chosen to 
register the kind smoked more than 50%, which is, of course, a rough calculation. Brands of 
cigarettes and tobacco were grouped according to tobacco and tar contents and filter, as many 
patients have used several different brands, but often within similar tobacco-strengths. Some 
authors define HRC-smokers as smoking strictly pack tobacco(8), while others refer more 
generally(38).  
Several patients have alternated between hand rolled cigarettes (HRC) and fabricated 
cigarettes (FC), and the 5% increased occurrence of adenocarcinoma compared to country-
mean could indicate consumption of more fabricated “light” cigarettes, which, due to content 
and smoking pattern, are shown to induce more adenocarcinomas(96).However, we believe 
that most smokers report correctly concerning which type of cigarettes they have used mostly, 
also because they have reported number of packs of tobacco weekly in cases of using HRC. 
Average number of daily cigarettes smoked was 15 in the HRC group. This is comparable 
with a large population survey(97), and shows that those who develop cancer are not 
necessarily excessive smokers, but that the group has several other known risk factors on 
their behalf, such as early smoking debut, long duration of smoking and no filter(98-100).  
This study has taught us that it is difficult to register detailed facts on smoking in a 
perspicious way.   
9.2.3.2 Risk estimate 
The calculated odds ratio of 13 of developing lung cancer if smoking HRC compared to FC is 
a very coarse calculation, based on several discussable assumptions, stipulating that the 
36
remaining smoking population in the region are all healthy, and assuming a smoking pattern 
in Agder comparable to the national average regarding brand, type and quantity. An OR of 13 
seems, also to us, high, and is most likely an over-estimation. However, missing all sales data 
from the tobacco companies, we have no better numbers to base our calculations on. 
DeStéfani indicates a 30% increased risk for lung cancer in smokers of HRC in Uruguay(35), 
supporting our assumptions, but such comparisons between countries and continents are not 
straight forward. Very recent data indicate substantial national differences in carcinogenic 
contents of tobacco(101). No exact survey on the detailed contents on tobacco products exist 
world wide. Thus, locally produced pack tobacco might even contain more carcinogens than 
known, comparable brands from former testing. However, these are only assumptions, and 
cannot be further investigated due to lacking cooperation from the local tobacco companies. 
9.2.3.3 Addiction 
As found previously(102), still no more than half of the patients had quitted smoking before 
lung cancer was diagnosed. One third of former smokers had quitted within the last year 
before diagnosis. Smokers often seem to wait until serious symptoms appear before quitting. 
As lung cancer often starts with no or unspecific  symptoms, similar to previously 
experienced in periods (bronchitis, cough and phlegm), increased attention should be paid on 
informing and motivating smokers to quit before developing serious symptoms and cancer. In 
a recent survey, Lund(8) showed that smokers of HRC often believed pack tobacco to be less 
hazardous for their health than FC. Smokers of HRC are often characterized as more addicted 
to nicotine and as having more difficulties quitting, than those smoking FC(103). Similarly, 
smokers starting at a young age often have more difficulties quitting later(8). 
9.2.3.4 Demands for action 
The Norwegian authorities have recently banned smoking in public, in restaurants and in 
most schools, thereby reducing the incidence of smoking in the population and especially 
among the teenagers. Pack tobacco is still less expensive than fabricated cigarettes, and is 
thus more used by adolescents with a tight economy and early smoking debut. Taxes have 
recently been raised, thus making both kinds of cigarettes more expensive and more 
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comparable in price. These actions reduce early smoking debut, and especially early start with 
pack tobacco, which may seem more addictive than FC. 
For comparison, the consumption of HRC is reported to rise again in other developed 
countries, due to price-differences, similar to the previous situation in Norway(103;104). 
Although we suggest FC carrying a somewhat lower risk of developing lung cancer than 
HRC, ninety-five percent of patients developing lung cancer in Southern Norway were ever-
smokers. Primarily, avoiding smoking debut, secondarily, increasing quit-rates among 
smokers are the most important efforts for reducing the incidence of this serious disease. 
38
10 Conclusion, clinical implications and future 
perspectives 
10.1 Conclusion  
This study showed that the delays in the diagnostic process were according to international 
recommendations in 52 to 71% of cases, and revealed thereby several potentials for 
improvement.  
We have not been able to establish the reason for the high incidence of lung cancer in 
Southern Norway, except the finding that nine out of ten ever smokers developing lung 
cancer in the region reported having smoked primarily hand-rolled cigarettes. This, together 
with a clearer dose-response relationship among smokers of HRC than FC among those 
developing lung cancers, leaves a distinct suspicion that HRC are more carcinogenic than the 
worldwide more commonly used, fabricated cigarettes (FC). 
In this unselected sample of patients with lung cancer, HRQOL was reported worse than in 
reference values from other studies of more selected groups, documenting a higher burden of 
illness than previously shown. Mood disorders were common and associated with reduced 
functions and increased symptoms compared to those without anxiety or depression.  
The changes in HRQOL after first treatment modality were mostly correlated with disease 
progression and side-effects of treatment. Patients with mood disorders may be a group of 
patients which could profit from more information and closer follow-up to reduce symptoms 
in future. 
Patients receiving active tumour reducing treatments were more willing to repeat or 
recommend the same treatment sequence than those who received BSC only. 
We also find a need for developing new tools for evaluating HRQOL in unselected patient 
populations. 
10.2 Clinical implications 
The survey showed that some patients are referred under misleading diagnoses or symptoms, 
such as “cough”, not necessarily leading to hasty admittance or primarily cancer-directed 
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examinations if not mentioned in the referral letter. We have later informed GPs in the region 
about the necessity of expressing a suspicion of malignancy, if any, to facilitate rapid 
examinations. In order to shorten specialist delay, we have started to refer some patients 
directly to tru-cut lung biopsy as first examination, instead of bronchoscopy, if tumour is 
peripheral. Resources are, recently, added specifically to increase efficiency in diagnosing 
malignant tumours of the lung, i.e. endoscopic ultrasound (EUS) guided fine needle 
aspiration cytology (FNAC) along the oesophagus and endobronchial ultrasound (EBUS) 
guided FNAC. 
Because our findings indicate that patients with mood disorders have reduced function and 
more symptoms from their disease, they may need more information and closer follow-up 
throughout the diagnostic process and treatment. We now have a lung cancer out-patient 
clinic with trained nurses being available 2 to 3 days a week, and a responsible physician, 
answering calls and extra visits whenever needed by patients with lung cancer. Patient feed-
back on this is utterly positive.  
The authorities have done important legislative changes to reduce general tobacco 
consumption in Norway. We still find it of utmost importance to inform the public about the 
increased risk of smoking hand-rolled cigarettes compared to fabricated, even though no 
smoking is the most desirable goal for the entire population. 
10.3 Future perspectives 
Since initiating this study, important changes in smoking habits have taken place. Smoking 
was prohibited in public places in Norway in 2003 and smoking was banned from all 
restaurants June 1, 2004(105). Taxes on hand-rolled tobacco are somewhat raised, but still do 
not equal fabricated cigarette prices.  
All together, the Norwegian policymakers have done significant measures to reduce tobacco 
smoking, and the prevalence of daily smokers has been reduced to 21% of adults among both 
genders in 2008. Accordingly, the incidence of lung cancer in Norway is expected to fall 
throughout the next 30 years, as well as several cardiovascular diseases and COPD.  
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It is still desirable to get an overview of the market share of pack tobacco sold and used in the 
region of Southern Norway, though the smoking incidence is rapidly falling. Hopefully this 
detail can be implemented in the next large statistical survey on smoking habits. Further, a 
future study measuring residential radon in the homes of lung cancer patients in Agder would 
still be very interesting, and this has also been expressed by patients themselves.   
HRQOL questionnaires, HAD and SoC have not been implemented in the daily surveillance 
of lung cancer patients in our clinic, but we have learned that patients expressing signs of 
anxiety or depression may percept more symptoms of disease and treatment, and should 
possibly be met with more information and more frequent follow-up.  
Data on survival of this unselected patient population receiving different treatment regimes 
will be analyzed later. 
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12 Appendix I-VI  
(English versions: number+b)  
Appendix 
no 
Norwegian title English title 
I EORTC QLQ C30 (version 3.0) og LC13  EORTC QLQ C30 & LC13 
II HAD (Hospital anxiety and depression 
scale)  
HAD 
III Livsorientering (Sense of Coherence 13)  Sense of Coherence 
IV Pasienterfaringer IVb Patient experiences 
V Spørreskjema ved diagnose Questions at baseline–see appendix, paper 
III 
VI Tjære og nikotin i sigaretter på det norske 
markedet 
Tar and nicotine levels in tobacco brands 
on the Norwegian market (Norwegian 
only) 
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Appendix I 
EORTC  QLQ - C30    (version 3.0.)  
Vi er interessert i forhold vedrørende deg og din helse. Vær så vennlig å besvare hvert spørsmål ved å
sette en ring rundt det tallet som best beskriver din tilstand. Det er ingen “riktige” eller “gale” svar. 
Alle opplysningene vil bli behandlet konfidensielt.
       Ikke i det             Svært 
hele tatt  Litt  Endel            mye 
1. Har du vanskeligheter med å utføre anstrengende 
aktiviteter, slik som å bære en tung handlekurv 
    eller en koffert?                                                           1              2             3               4    
2. Har du vanskeligheter med å gå en lang tur?                1              2             3               4 
3. Har du vanskeligheter med å gå en kort tur utendørs?  1              2     3           4 
4. Er du nødt til å ligge til sengs eller sitte i en stol 
i løpet av dagen?               1   2     3           4 
     
5. Trenger du hjelp til å spise, kle på deg, vaske deg 
eller gå på toalettet?              1  2     3           4 
I løpet av den siste uka:    Ikke i det           Svært 
  hele tatt         Litt           Endel           mye 
6. Har du hatt redusert evne til å arbeide eller 
utføre andre daglige aktiviteter?           1  2     3  4 
7. Har du hatt redusert evne til å utføre dine 
hobbyer eller andre fritidsaktiviteter?          1  2     3  4 
8. Har du vært tung i pusten?           1  2     3  4 
9. Har du hatt smerter?            1  2     3  4 
10. Har du hatt behov for å hvile?                  1  2     3  4 
11. Har du hatt søvnproblemer?          1  2     3  4 
12. Har du følt deg slapp?            1  2     3  4
13. Har du hatt dårlig matlyst?                                        1              2             3                  4 
14. Har du vært kvalm?            1  2     3  4 
I løpet av den siste uka:     Ikke i det                   Svært 
       hele tatt  Litt  Endel        mye 
15. Har du kastet opp?          1    2     3  4 
16. Har du hatt treg mage?          1    2     3  4
17. Har du hatt løs mage?          1    2     3  4 
18. Har du følt deg trett?          1    2     3  4
19. Har smerter påvirket dine daglige aktiviteter?      1    2     3  4 
20. Har du hatt problemer med å konsentrere deg, 
f.eks. med å lese en avis eller se på TV?        1|               2     3  4 
21. Har du følt deg anspent?          1    2     3  4 
22. Har du vært engstelig?         1    2     3  4 
23. Har du følt deg irritabel?          1    2     3   4 
24. Har du følt deg deprimert?         1    2     3   4 
25. Har du hatt problemer med å huske ting?       1    2     3   4 
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26. Har din fysiske tilstand eller medisinske behandling 
påvirket ditt familieliv?           1   2     3   4
27. Har din fysiske tilstand eller medisinske behandling 
påvirket dine sosiale aktiviteter?          1    2     3   4 
28. Har din fysiske tilstand eller medisinske behandling 
gitt deg økonomiske problemer?          1    2     3   4 
Som svar på de neste spørsmålene sett en ring rundt det tallet fra 1 til 7 
som best beskriver din tilstand 
29. Hvordan har din helse vært i løpet av den siste uka?   
1  2  3  4  5  6  7 
       Svært       Helt 
      dårlig       utmerket 
30.Hvordan har livskvaliteten din vært i løpet av den siste uka? 
1  2  3  4  5  6  7 
      Svært       Helt 
     dårlig       utmerket 
EORTC  QLQ - LC13  
Endel pasienter opplever av og til at har noen av følgende symptomer eller problemer. Vær vennlig å 
angi i hvilken grad du har hatt disse symptomene  eller problemene i løpet av den siste uka. Sett en 
ring rundt det tallet som best beskriver din tilstand. 
I løpet av den siste uka:         Ikke I det            Svært 
                                                                                                    hele tatt Litt   Endel        mye 
31. Hvor mye har du hostet ? 1 2 3 4 
32. Har du hostet blod ? 1 2 3 4 
33. Har du vært tungpustet i hvile ? 1 2 3 4 
34. Har du vært tungpustet når du har gått ? 1 2 3 4 
35. Har du vært tungpustet når du har gått i trapper ? 1 2 3 4 
36. Har du vært sår i munnen eller på tungen ? 1 2 3 4 
37. Har du hatt svelgproblemer ? 1 2 3 4 
38. Har du hatt prikkinget (stikninger) i hendene eller i bena ?  1 2 3 4 
39. Har du hatt håravfall ? 1 2 3 4 
40. Har du hatt smerter i brystet ? 1 2 3 4 
41. Har du hatt smerter i arm eller skulder ? 1 2 3 4 
42. Har du hatt smerter i andre deler av kroppen ? 1 2 3 4 
 Hvis ja, hvor har du hatt vondt ? ______________________ 
43. Har du brukt smertestillende medisiner ?    1. Nei        2. Ja 
 Hvis Ja, hvor mye har det hjulpet ? 1 2 3 4 
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Appendix II 
HAD 
Følelser spiller en stor rolle ved de fleste sykdommer. Her kommer noen spørsmål om hvordan du 
føler deg.  
For hvert spørsmål krysser du av for ett av de fire svarene som best beskriver dine følelser den sisten 
uken. Ikke tenk for lenge på svaret – de spontane svarene er best. 
(Fylles ut av pasienten) 
1. Jeg føler meg nervøs og urolig  
   -mesteparten av tiden         
    -mye av tiden   
-fra tid til annen  
-ikke i det hele tatt  
2. Jeg gleder meg fortsatt over tingene slik jeg pleide før  
-avgjort like mye  
-ikke fullt så mye  
-bare lite grann  
-ikke i det hele tatt  
3. Jeg har en urofølelse som om noe forferdelig vil skje  
-ja, og noe svært ille  
-ja, ikke så veldig mye  
-litt, bekymrer meg lite 
-ikke i det hele tatt  
4. Jeg kan le og se det morsomme i situasjoner  
   -like mye nå som før  
-ikke like mye nå som før 
-avgjort ikke som før  
-ikke i det hele tatt  
5. Jeg har hodet fullt av bekymringer   
   -veldig ofte   
-ganske ofte   
-av og til   
-en gang i blant  
6. Jeg er i godt humør     
   -aldri    
-noen ganger   
-ganske ofte     
-for det meste   
7. Jeg kan sitte i fred og ro og kjenne meg avslappet 
-ja, helt klart   
-vanligvis   
-ikke så ofte   
-ikke i det hele tatt  
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8. Jeg føler meg som om alt går langsommere  
-nesten hele tiden  
-svært ofte   
-fra tid til annen  
-ikke i det hele tatt  
9. Jeg føler meg urolig som om jeg har sommerfugler i magen  
-ikke i det hele tatt  
-fra tid til annen  
-ganske ofte   
-svært ofte   
10. Jeg bryr meg ikke lenger om hvordan jeg ser ut   
-ja, jeg har sluttet å bry meg        
-ikke som jeg burde         
-kan hende ikke nok  
-bryr meg som før  
11. Jeg er rastløs som om jeg stadig må være aktiv   
-uten tvil svært mye  
-ganske mye   
-ikke så veldig mye  
-ikke i det hele tatt  
12. Jeg ser med glede frem til hendelser og ting   
-like mye som før  
-heller mindre enn før 
-avgjort mindre enn før 
-nesten ikke i det hele tatt 
13. Jeg kan plutselig få en følelse av panikk    
-uten tvil svært ofte    
-ganske ofte      
-ikke så veldig ofte    
-ikke i det hele tatt    
14. Jeg kan glede meg over gode bøker, radio og TV  
-ofte    
-fra tid til annen    
-ikke så ofte     
-svært sjelden     
Appendix III 
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Livsorientering (Sense of Coherence 13) 
          
Her kommer noen spørsmål som kan være litt vriene å svare på, men gjør så godt du kan, og ikke bli 
gående og grunne altfor lenge før du krysser av i den ruten som passer for ditt svar. 
Svarene blir behandlet fortrolig, og kun til forskningsformål.  
 -fylles ut av pasienten.               Kryss av i den ruten som passer for ditt svar 
1. Har du følelsen av at du egentlig ikke bryr deg om hva som foregår rundt deg? 
       
Svært sjelden                        Svært ofte eller aldri 
2. Har det hendt at du ble overrasket over oppførselen til personer som du trodde du kjente 
godt? 
       
        Har aldri hendt                                 Har ofte hendt 
3. Har det hendt at personer som du hadde regnet med, skuffet deg? 
       
Har aldri hendt                                                Har ofte hendt 
4. Hittil har livet ditt: 
       
Helt savnet                Gjennomgående 
mål og mening         hatt mål og mening 
5. Føler du deg urettferdig behandlet? 
       
Svært ofte          Svært sjelden eller aldri 
6. Har du noen ganger følelsen av at du er i en ukjent situasjon og ikke vet hva du skal gjøre? 
       
Svært ofte                   Svært sjelden eller aldri 
7. Å gjøre de tingene du gjør hver dag, er: 
       
En til glede            En kilde til smerte 
og dyp tilfredsstillelse                 og kjedsomhet 
8. Har du svært motstridende tanker og følelser? 
       
Svært ofte                    Svært sjelden eller aldri 
9. Hender det at du har følelser inne i deg som du helst ikke vil føle? 
       
Svært ofte                    Svært sjelden eller aldri 
10. Mange mennesker – selv de med sterk selvfølelser – føler seg iblant som en ”ulykkesfugl”. 
Hvor ofte har du kjent det slik? 
       
Aldri          Svært ofte 
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11. Når et eller annet har hendt, har du da vanligvis oppdaget at: 
       
Du overvurderte eller              Du så saken i sin 
Undervurderte dets betydning                    rette proporsjon 
12. Hvor ofte føler du at det ikke er noen mening i det du gjør i ditt daglige liv? 
       
Svært ofte                             Svært sjelden eller aldri 
13. Hvor ofte har du følelser som du ikke er sikker på at du kan holde under kontroll? 
       
Svært ofte                              Svært sjelden eller aldri 
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Appendix IV 
Pasienterfaringer 
Vi ønsker å spørre om dine erfaringer i kontakten med sykehuset i behandlingen av din 
kreftsykdom. 
Du skal nå kun svare på dine erfaringer 
ved diagnose    -ved operasjon           -ved strålebehandling      
 -ved cellegiftbehandling   -ved oppfølging med Best Supportive Care   
Vennligst kryss av i én av rutene for hvert spørsmål. (Svarene vil bli behandlet anonymt.) 
1. Når det gjelder behandlingen du har mottatt for din lungesykdom, hva synes du om  
   lungeseksjonen?           kirurgisk avdeling?   Senter for Kreftbehandling? 
 Til denne behandlingsenheten har jeg: 
Ingen tillit 
1
Liten tillit 
2 
Stor tillit      
3 
Meget stor 
tillit    4 
Svært stor 
tillit    5 
     
2. Hva synes du alt i alt om den pleie og medisinske behandlingen du har fått ved sykehuset? 
 Jeg er: 
Svært 
utilfreds 
1
Meget 
utilfreds 
2
Utilfreds 
3 
Verken 
tilfreds eller 
utilfreds    4
Tilfreds       
5
Meget 
tilfreds 
6
Svært 
tilfreds 
7 
       
3. Når det gjelder mine muligheter til å fortelle personalet om alt som var viktig om min 
lungesykdom, er jeg: 
Svært 
utilfreds 
1
Meget 
utilfreds 
2
Utilfreds 
3 
Verken 
tilfreds eller 
utilfreds    4
Tilfreds       
5
Meget 
tilfreds 
6
Svært 
tilfreds 
7 
       
4. Hva synes du om legenes informasjon til deg? 
 Den informasjonen legene ga meg var: 
Svært lite 
forståelig 
1
Meget lite 
forståelig 
2 
Lite 
forståelig 
3 
Verken 
eller 
4
Godt 
forståelig 
5 
Meget godt 
forståelig 
6
Svært godt 
forståelig 
7 
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5. Har du fått vite det du syntes var nødvendig om hvordan undersøkelser skulle foregå mens 
lungesykdommen ble utredet? 
Nei, jeg 
fikk ikke 
vite noe  1
Jeg fikk vite 
for lite  
2 
Jeg fikk vite 
en del 
3
Jeg fikk vite 
det meste 
4
Ja, jeg fikk 
vite alt jeg 
trengte  5 
     
6. Føler du at legene har hatt omsorg for deg? 
 Jeg føler at legene har hatt: 
 Svært liten 
omsorg 
1
Liten 
omsorg 
2
Verken  
eller  
3
Stor  
omsorg 
4 
Svært stor 
omsorg 
5 
     
7. Føler du at sykepleierne har hatt omsorg for deg? 
 Jeg føler at sykepleierne har hatt: 
 Svært liten 
omsorg 
1
Liten 
omsorg 
2
Verken  
eller  
3
Stor  
omsorg 
4 
Svært stor 
omsorg 
5 
     
8. Har du opplevde at det har vært én lege som har hatt hovedansvaret for deg under oppholdet? 
  Ja    Nei   
9. Hadde du, da du forlot sykehuset, fått informasjon om hva som feilte deg? 
Nei, jeg 
fikk ikke 
vite noe  1
Jeg fikk for 
lite infor-
masjon  2 
Jeg fikk vite 
en del 
3
Jeg fikk vite 
det meste 
4
Ja, jeg fikk vite 
alt jeg trengte  
5 
     
Videre kommer noen spørsmål knyttet opp mot sykdommen og den gjennomgåtte 
behandlingen: 
10. Hvor belastende synes du denne behandlingen har vært for deg?  
Overhodet 
ikke plagsom  
5
Litt plagsom
4
Nokså 
plagsom 
3
Meget 
plagsom 
2
Sterkt 
plagsom 
1 
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  Ikke aktuelt   
11. Når det gjelder informasjonen du har fått om virkninger og bivirkninger av den behandling du 
har mottatt, er du: 
Svært 
utilfreds 
1
Meget 
utilfreds 
2
Utilfreds 
3 
Verken 
tilfreds eller 
utilfreds    4
Tilfreds       
5
Meget 
tilfreds 
6
Svært 
tilfreds 
7 
       
12. Dersom du skulle valgt om igjen; ville du da ha valgt å takke ja til denne behandlingen på 
nytt, med den kjennskap du nå sitter med , både med tanke på virkninger /bivirkninger av 
behandlingen, og sykdommens utvikling? 
Nei, helt 
sikkert ikke 
valgt samme 
behandling 
igjen          1
Mest trolig 
ikke valgt 
samme 
behandling 
igjen     2 
Neppe valgt 
samme 
behandling 
igjen 
3
Usikkert 
4 
Kanskje 
valgt  
samme 
behandling 
igjen    5
Mest trolig 
valgt samme 
behandling 
igjen 
6 
Ja, ville 
absolutt 
gjort samme 
valg igjen 
7 
       
13. Hvis en nær venn fikk samme sykdom som deg, ville du da ha anbefalt ham/henne å ta imot 
den samme behandling som du selv har mottatt? 
Ja, absolutt 
5
Mest 
sannsynlig 
4 
Usikkert 
3 
Mest 
sannsynlig 
ikke   2 
Nei, 
overhodet 
ikke    1 
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Appendix IVb 
Patient experiences 
We would like to ask you about your experiences with the hospital-division(s) during the 
treatment of your cancer. 
Please answer according to your experiences 
at diagnosis          -at surgery        -at radiation therapy  
at chemotherapy      -at follow-up with Best Supportive Care   
1. Concerning the treatment you have received, what is your opinion of the hospital department? 
(dept. of pulmonology / Centre of radiotherapy/ Surgical dept.) 
No trust  
1
Little trust  
2 
Trusted 
3 
Highly trusted  
4 
Very highly trusted  
5
     
2. What is your opinion of the nursing and medical treatment you received? 
Highly 
unsatisfying 
1 
Very 
unsatisfying 
2 
Unsatisfying 3 Neither 
satisfying 
nor 
unsatisfying 
4 
Satisfying 
5 
Very 
satisfying 
6 
Highly 
satisfying  
7 
       
3. Concerning my possibilities to explain important matters about my lung disease, I am 
Highly 
unsatisfied 
1 
Very 
unsatisfied 
2 
Unsatisfied 
3 
Neither 
satisfied nor 
unsatisfied 
4 
Satisfied  
5 
Very 
satisfied  
6 
Highly 
satisfied  
7 
       
4. What is your opinion of the physicians’ information to you? 
Definitely very 
little 
understandable 
1 
Very little 
understandable 
2 
Little 
understandable 
3 
Neither 
– nor 4 
Understandable 
5 
Very well 
understandable 
6 
Very well 
understandable
7 
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5. Have you been told what you find necessary about examinations to be performed during the 
diagnostic phase? 
No, I was told 
nothing 1 
I was told too 
little 2 
I was told 
some 3 
I was told 
most 4 
Yes, I was told everything I 
needed 5 
    
6. Do you feel that the physicians have cared for you?
No care 1 Little care 2 Some care 3 Good care 4 Very good care 5 
    
7. Do you feel that the nurses have cared for you? 
No care 1 Little care 2 Some care 3 Good care 4 Very good care 5 
    
8. Did you experience one specific physician to be mainly in charge of you? 
Yes        No   
9. Did you, upon leaving the hospital, have information concerning your disease? 
No, I was told 
nothing 1 
I received little 
information 2 
I received some  
information 3 
I received most 
information 4 
Yes, I was told 
all I needed 5 
    
The next questions concern treatment you have received. 
10. How straining has treatment been? 
Not straining at all 5 A bit straining 4 Rather straining 3 Very straining 2 Highly straining 1 
    
        Does not apply  
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11. Concerning information about effects and side-effects of the treatment you have received, are 
you 
Highly 
unsatisfied 
1 
Very 
unsatisfied 
2 
Unsatisfied 3 Neither 
satisfied nor 
unsatisfied 4 
Satisfied 5 Very 
satisfied 
6 
Highly 
satisfied 7 
      
  Does not apply   
12. If you were to choose again, would you, with your present experience concerning disease 
development, effects and side effects, accept the same treatment again? 
No, definitely 
not repeat 1 
Most 
probably not 
repeat 2 
Maybe not 
repeat 3 
Unsure 4 Maybe 
repeat 5 
Most 
probably 
repeat 6 
Yes, 
definitely 
repeat 7 
      
13. If a close friend or relative were to get the same disease, would you recommend him the same 
treatment as you have received? 
Yes, definitely 
recommend 5 
Most probably 
recommend 4 
Unsure 3 Most probably not 
recommend 2 
No, definitely not 
recommend 1 
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Appendix V 
Spørreskjema ved diagnose 
RØYKING        fylles ut av pasienten
1. Røyker du nå? (siste 6 måneder)        
Ja                  Nei   
Daglig røyker           Aldri røyker        (gå videre til sp.mål 9) 
12.1.1.1.1.1.1 Røyker av og til      Tidligere røyker 
(mindre enn 1sig. daglig) 
Hvis du har sluttet å røyke, hvor gammel var du da du sluttet? _ _ _ år 
2. Alder ved røykestart: _ _ år    
3. Hvilket sigarettmerke /tobakksmerke har du røkt mest? (Se vedlegg hvis i 
tvil)________________________________ 
Har du alltid røkt filtersigaretter?   Ja    Nei      -hvis nei: 
• Hvor stor andel av sigarettene du har røkt har vært hjemmerullede? _ _ _% (eks.25%, 50% 
osv.) 
• Hvor stor andel av sigarettene du har røkt har vært med filter?          _ _ _ % 
• Hvor stor andel av tobakken du har røkt har vært pipe?                     _ _ _ % 
4. Hvor mange sigaretter/hjemmerullede sigaretter har du gjennomsnittlig røkt per dag ?          
  _ _ _ sigaretter  
5. Hvor mange sigaretter/hjemmerullede sigaretter har du røkt på det meste per dag?          
  _ _ _ sigaretter 
6. Hvis rulletobakk eller pipe; hvor mange pakker har du gjennomsnittlig røkt per uke?  
 _ _ _  pakker 
7. Hvis rulletobakk eller pipe; hvor mange pakker har du på det meste røkt per uke?  
 _ _ _ pakker      
   
YRKE, SIVILSTAND 
8. Hvilken skolegang har du fullført? (kryss av bare for høyeste utdanning)   
- 7-10 årig grunnskole /middelskole         
- yrkesfaglig videregående /yrkesskole /handelsskole       
      -    artium /allmennfaglig retning videregående skole / - økonomisk gymnas  
          
- fullført 1-3årig høyskole eller universitetsstudium       
      -    fullført utdanning ved høyskole eller universitet av - 4 års normert varighet eller mer  
         
9. Hvilket yrke har du? (hvis flere; nevn det/de yrker du har hatt lengst)  ______________        
(industriarbeider , kontorist   primærnæring  , snekker/rørlegger , annet  )  
10. Har du, så vidt du vet selv, vært eksponert for mulige skadelige stoffer gjennom jobben? I så fall, 
hva og hvor lenge?     
Asbest   _ _ år  Mineralstøv  _ _ år 
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Nikkel   _ _ år  Annet   _ _ år   -Hva?__________ 
11. I hvilken grad er du yrkesaktiv? 
I full jobb  
Arbeidsledig  
Sykmeldt     _ _ _ %  Fra dato _ . . _ _ _ til _ . . _ _ _  
Ufør / på attføring 
Pensjonist  
Hjemmeværende 
12.  Hva er din sivilstatus? Gift /samboer   Skilt /separert   Enslig    Enke /-mann 
   
13. Røyker din partner/ livsledsager (gjelder også tidligere, langvarig livsledsager)?   
Ja       Nei        Har ingen partner    
15. I hvor mange år har du bodd sammen med andre røykere? _ _ år (Hvis uaktuelt, skriv ”0”) 
16. Har du god kontakt med andre mennesker, et ”nettverk” som du føler at du kan betro deg til / 
noen å snakke med om problemer?    Ja    Nei    Usikker   
ANDRE SYKDOMMER, SYMPTOMER 
17. Har du fra tidligere vært syk med (kryss av ):           Ja  Nei
Astma?                  
Kronisk obstruktiv lungesykdom (KOLS/emfysem/ kronisk bronkitt)?      
Hjertesykdom (infarkt, angina pectoris)?              
Høyt blodtrykk eller hjerneslag?               
Annen kreftsykdom?                 
”Røykebein”      |            
18. Hvilke plager var det som gjorde at du gikk til lege for den sykdommen som nå er oppdaget? 
(kryss av for en eller flere) 
Økt tungpust         Slapphet     
Smerter      Hoster opp blod      
Hoste        Lungebetennelse     
Heshet       Krampeanfall  
Vekttap      Annet       
Svelgbesvær       Ingen symptomer    
19. Når merket du først de plagene som du nå ser at hadde sammenheng med lungekreft- 
sykdommen? _ . . _ _ _ (dag/mnd/år) 
20. Når kontaktet du første gang lege for den sykdommen som nå er oppdaget?  
_ . . _ _ _ (dag/mnd/år) 
21. Når ble du henvist videre til spesialist for utredning? _ . . _ _ _ (dag/mnd/år) 
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Appendix VI 
Tjære og nikotin i sigaretter på det norske 
markedet  
Sigarettype (sortert etter nikotininnhold) Mengde tjære
Mengde 
nikotin
Filtersigaretter mg mg
Barclay Number One 1 0,1
Barclay Number One Mentol 1 0,1
Barclay Ultra Lights 2 0,2
Dunhill Super Lights 4 0,4
Merit Ultra Lights (blå) 4 0,4
Merit Ultra Lights Mentol 4 0,4
Merit Ultra Lights 100 5 0,4
Barclay 100 mm 5 0,5
Barclay 5 0,5
Barclay Mentol 5 0,5
Merit 7 0,5
Dunhill Lights 6 0,6
Dunhill Lights Menthol 6 0,6
Camel Extra Lights 7 0,6
Marlboro Lights 8 0,6
Cooly Light Menthol 7 0,7
Camel Lights 8 0,7
Lucky Strike Lights 8 0,7
Salem Lights Menthol 8 0,7
Winston Lights 8 0,7
Pall Mall Lights 8 0,7
Marlboro Lights 100 9 0,7
Kent 9 0,7
Winchester Lights 12 0,7
Camel Medium 10 0,8
Pall Mall Mild 11 0,8
Marlboro Medium 11 0,8
Prince Extra Mild 9 0,9
Prince Extra Mild 100 9 0,9
Petterøe Extra Mild KS Filter 9 0,9
Dunhill Menthol 11 0,9
Winston Lights 100 11 0,9
Petterøe’s Mild KS Filter 11 0,9
Biltmore Light 11 0,9
Mento 11 0,9
Benson & Hedges 12 0,9
Dunhill Filter 12 0,9
Rothmans Filter 12 0,9
Lucky Strike 12 0,9
South State KS 13 0,9
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Marlboro 13 0,9
Marlboro 100 13 0,9
Prince Mild 12 1,0
Prince Mild 100 12 1,0
Prince Mild Menthol 12 1,0
Cooly Menthol 13 1,0
Pall Mall Mild 13 1,0
Pall Mall Filter 14 1,0
More Grønn Menthol 14 1,0
More Rød 14 1,0
Winchester 15 1,0
Blue Master 14 1,1
Petterøe’s KS Filter 14 1,1
Winston Filters 100 15 1,1
Winston Filters 15 1,2
Craven «A» Filter 15 1,2
Camel Filters 15 1,2
Salem Filter Menthol 15 1,2
Prince 14 1,3
Prince 100 14 1,3
Tiedemanns Rød 15 1,5
Uten filter mg mg
Camel 15 1,2
Craven A Plain Tip 15 1,2
Pall Mall 15 1,2
South State KS 15 1,3
Teddy 15 1,3
Innhold av nikotin, tjære og karbonmonoksyd i håndrullede sigaretter  
(Alle data pr. sigarett/i mg per sigarett)  
Merke Type
Nikotin-
innnhol
d
Tjære-
innhold
Karbon-
monoks
yd
Petterøe’s 3 
Blanding Håndrullet 2,67 34,21 21,97
Petterøe’s 3 Mild Håndrullet 1,99 32,68 22,10
Petterøe’s 3 Extra 
mild Håndrullet 1,92 31,56 21,55
Eventyr 3 Blanding Håndrullet 2,68 35,93 22,81
Eventyr 3 Mild Håndrullet 2,48 35,49 22,20
Gull Snitt Håndrullet 3,02 34,67 22,13
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Petterøe’s 3 
Blanding Hylse m/filter 1,88 21,50 18,94
Petterøe’s 3 Mild Hylse m/filter 1,28 20,36 19,05
Petterøe’s 3 Extra 
mild Hylse m/filter 1,25 20,05 19,05
Teddy  1,40 22,00 13,00
  
Kilde: Målingene av nikotin, tjære og karbonmonoksyd i rulletobakken er foretatt av Chemisches 
Laboratorium Dr. L. Herzfeld AG, Basel i januar 1994. 
Tabeller og diagram er utarbeidet av Statens tobakksskaderåd. Mars 1999 . 
